An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients With Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)
Latest Information Update: 10 Dec 2025
At a glance
- Drugs Pegcetacoplan (Primary) ; Pegcetacoplan (Primary)
- Indications Thrombotic microangiopathy
- Focus Pharmacokinetics; Registrational
- Sponsors Swedish Orphan Biovitrum
Most Recent Events
- 28 Nov 2025 Actual primary completion date changed from 25 Nov 2024 to 8 Dec 2024.
- 19 Dec 2024 Status changed from active, no longer recruiting to completed.
- 05 Nov 2024 According to an Apellis Pharmaceuticals media release, topline data from this study are expected in mid-2025.